Buradasınız

Anasayfa » Content

Kalp Yetmezliğinde Kromogranin A

Chromogranin A in Heart Failure

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
In chronic heart failure, several hormonal systems are activated with diagnostic and prognostic implications. Chronic heart failure is a complex syndrome characterized by neuroendocrine activation: catecholamines, natriüretic peptides and components of renin-angiotensin system all chronic heart failure. Serum Chromogranin-A (CgA), that is an acid protein of 49 kDa, presents in the secretuar granules of neuroendocrine cells and increases in chronic heart failure. Increased CgA levels are related to the clinical severity of the chronic heart failure and predictive factor for mortality
Bookmark/Search this post with
Abstract (Original Language): 
Kronik kalp yetmezliğinin (KKY) tanı ve prognozundan çeşitli hormonal sistemlerin aktivasyonu sorumludur. KKY katekolaminlerin, natriüretik peptidlerin ve renin-anjiotensin sistem kompanentlerinin artışının olduğu nöroendokrin aktivasyonla karakterize kompleks bir sendromdur. Nöroendokrin hücrelerin sekretuar granüllerinde 49 kDa ağırlığında asit bir protein olarak bulunan kromogranin A’nın (CgA), KKY’de serum düzeyleri artmaktadır. Cg A artmış düzeyleri kalp yetmezliğinin klinik şiddetiyle ilişkili olup, mortalite için de prediktif faktördür
FULL TEXT (PDF): 
PDF icon arastirmax-kalp-yetmezliginde-kromogranin.pdf
  • 2
83-86
  • Turkish

REFERENCES

References: 

1. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S,
Simon A. Plasma noradrenaline, plasma renin activity, and
congestive heart failure. Circulation 1993; 87: 40 – 8.
2. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K.
Plasma endothelin determination as a prognostic indicator of 1-
year mortality after acute myocardial infarction. Circulation
1994; 89: 1573–9.
3. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre
G, Escolano S, Thomas D, Komajda M. Prognostic value of
plasma endothelin-1 in patients with chronic heart failure. Eur
Heart J 1997; 18: 254 – 8.
4. Omland T, Dickstein K, Syversen U. Association between
Plasma Chromogranin A Concentration and Long-term
Mortality after Myocardial Infarction. Am J Med 2003; 114:25-
30.
5. Banks P, Hele K. The release of protein from the stimulated
adrenal medulla. Biochem J. 1965.97, 40 – 1.
6. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the
first 25 years and future perspectives. Neuroscience 1992; 49:
497–528.
7. Mouland AJ, Bevan S, White JH, Hendy GN. Human
chromogranin-A gene. Molecular cloning, structural analysis,
and neuroendocrine cell-specific expression. Biol Chem 1994;
269: 6918–26 A. Altın, ark.
86
8. Tota B, Quintieri AM, Di Felice V, Cerra MC. New biological
aspects of Chromogranin A- derived peptides: Focus on
vasostatins Comp Biochem Physiol 2007 baskıda.
9. Metz-Boutigue MH, Garcia – Sablone P, Hogue – Angeletti R,
Auris D. Intracellular and extracellular processing of
chromogranin A. Determination of cleavage sites. Eur J
Biochem 1993; 217(1) :247- 57
10. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M,
Colombo B, Parrinello G, Corti A, Chromogranin A in heart
failure; a novel neurohumoral factor and a predictor for
mortality. Eur Heart J 2002; 23: 967 – 74.
11. Corti A. Chromogranin A in Tumor and Vascular Biology In:
Borges R, Gandia L (eds) Cell Biology of the Chromaffin Cell.
Spain; Instituto Teofilo Hernando, 2004; 117 – 28
12. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor
necrosis factor alpha in heart failure. Adv Exp Med Biol 2000;
482: 351 - 59.
13. Estensen ME, Hognestad A, Syversen U, Sguire I, Leong NG,
Kjekshus J, Dickstein K, Omland T. Prognostic value of plasma
chromogranin A levels in patients with complicated myocardial
infarction. Am Heart J 2006; 152: 927

Thank you for copying data from http://www.arastirmax.com